iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. iRhythm Technologies, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
IPO Year: 2016
Exchange: NASDAQ
Website: irhythmtech.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/4/2024 | $78.00 | Neutral | Goldman |
| 6/20/2024 | $115.00 | Peer Perform → Outperform | Wolfe Research |
| 12/11/2023 | $110.00 | Neutral → Buy | Citigroup |
| 7/19/2023 | $130.00 | Outperform | Robert W. Baird |
| 2/7/2023 | $150.00 | Overweight | Wells Fargo |
| 11/7/2022 | Underperform → Peer Perform | Wolfe Research | |
| 6/9/2022 | $180.00 → $155.00 | Buy → Neutral | Citigroup |
| 4/6/2022 | $105.00 | Underperform | Wolfe Research |
| 2/24/2022 | $167.00 → $151.00 | Overweight | Morgan Stanley |
| 2/24/2022 | Hold → Buy | Needham |
SAN FRANCISCO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company will be participating in the upcoming Citi 2024 Global Healthcare Conference. iRhythm's management is scheduled to participate in a fireside chat on Wednesday, December 4, 2024, at 10:15 am Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Events & Presentations" section of the company's investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc.iRhythm is a leading digital health
SAN FRANCISCO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) today announced the results of five new studies presented at the American Heart Association's 2024 Scientific Sessions in Chicago, IL. The findings underscore iRhythm's commitment to advancing ambulatory cardiac monitoring services to improve patient outcomes, enhance healthcare resource utilization, and provide access to affordable care, including for patients with chronic conditions. The five studies presented by iRhythm span three focus areas for long-term continuous monitoring (LTCM): patient engagement and satisfaction through digital tools and patient-centered product enhancements, evaluating a
SAN FRANCISCO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company will be participating in the upcoming Wolfe Research 2024 Healthcare Conference. iRhythm's management is scheduled to participate in a fireside chat on Tuesday, November 19, at 9:50 am Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Events & Presentations" section of the company's investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc.iRhythm is a leading digital health care
Zio AT device, along with the Zio ECG Utilization Software (ZEUS) (K222389), enables the provision of ambulatory Mobile Cardiac Telemetry (MCT) monitoring service for non-critical care patients FDA 510(k)-cleared enhancements will be available in 2025 SAN FRANCISCO, Oct. 30, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the U.S. Food and Drug Administration (FDA) has granted clearance for its 510(k) submission related to design modifications and labeling updates for the Zio AT device. Zio AT remains commercially available on
SAN FRANCISCO, Oct. 30, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended September 30, 2024. Third Quarter 2024 Financial Highlights Revenue of $147.5 million, an 18% increase compared to third quarter 2023Gross margin of 68.8%, a 260-basis point increase compared to third quarter 2023Unrestricted cash, cash equivalents and marketable securities of $522.0 million as of September 30, 2024 Recent Operational Highlights Strong quarterly registration volume driven by record demand from existing
Hypertrophic cardiomyopathy (HCM) is a genetic heart condition affecting about 1 in 500 people and is one of the leading causes of sudden cardiac death (SCD) in people under 35, including among athletes.1NSVT (nonsustained ventricular tachycardia), a known marker for increased risk of SCD in HCM, was detected in nearly 50% of HCM patients in the study undergoing long-term continuous ambulatory ECG monitoring of up to 14 days with a Zio® XT LTCM ECG patch device; 63% of NSVT episodes detected only after 48 hours, suggesting that Holter monitoring would miss the majority of episodes.NSVT episodes clinically judged to be higher risk were identified in 24% of the study population and were detect
SAN FRANCISCO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the U.S. Food and Drug Administration (FDA) has granted clearance for its 510(k) submission related to prior design changes made to the Zio AT device via letter to file. Zio AT remains commercially available on the market to ship to customers in the United States. "This clearance is related to modifications and certain enhancements to our Zio AT device previously made via letter to file and has been a priority for our teams to demonstrate iRhythm's commitment to
SAN FRANCISCO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the third quarter 2024 after the close of trading on Wednesday, October 30, 2024. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the presentation on the "Events & Presentations" section of the company's investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc. iRhythm is a lea
Zio ECG monitoring system is the only fourteen-day cardiac monitoring service in its category to receive Japanese regulatory approval as an improved device without a clinical trialZio ECG monitoring system previously received Japanese high medical needs designation, a unique distinction reflecting positive recommendation by the Japanese Heart Rhythm Society (JHRS)iRhythm will continue working towards reimbursement to enable market access in Japan, the world's second largest medical device marketJapan is the second largest ambulatory cardiac monitoring market in the world with an estimated 1.6 million tests prescribed annually – a number that is expected to continue to increase1-3 SAN FRAN
iRhythm's next-generation Zio® monitor demonstrated longer wear duration and analyzable time compared to the prior generation Zio® XT device.Longer wear duration and analyzable time may further improve diagnostic yield, building upon Zio XT service's superior yield among ambulatory cardiac monitoring services as demonstrated by the prior CAMELOT study findings.1The Zio monitor ECG device has been worn by over 1 million patients since launching in late 2023.2 SAN FRANCISCO, Sept. 09, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) today announced initial research findings on post-market, real-world performance of Zio® monitor, its next-generation Zio® long-term continuou
4 - iRhythm Technologies, Inc. (0001388658) (Issuer)
4 - iRhythm Technologies, Inc. (0001388658) (Issuer)
4 - iRhythm Technologies, Inc. (0001388658) (Issuer)
4 - iRhythm Technologies, Inc. (0001388658) (Issuer)
4 - iRhythm Technologies, Inc. (0001388658) (Issuer)
4 - iRhythm Technologies, Inc. (0001388658) (Issuer)
4 - iRhythm Technologies, Inc. (0001388658) (Issuer)
4 - iRhythm Technologies, Inc. (0001388658) (Issuer)
4 - iRhythm Technologies, Inc. (0001388658) (Issuer)
4 - iRhythm Technologies, Inc. (0001388658) (Issuer)
4 - iRhythm Technologies, Inc. (0001388658) (Issuer)
4 - iRhythm Technologies, Inc. (0001388658) (Issuer)
4/A - iRhythm Technologies, Inc. (0001388658) (Issuer)
SAN FRANCISCO, Oct. 30, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended September 30, 2024. Third Quarter 2024 Financial Highlights Revenue of $147.5 million, an 18% increase compared to third quarter 2023Gross margin of 68.8%, a 260-basis point increase compared to third quarter 2023Unrestricted cash, cash equivalents and marketable securities of $522.0 million as of September 30, 2024 Recent Operational Highlights Strong quarterly registration volume driven by record demand from existing
SAN FRANCISCO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the third quarter 2024 after the close of trading on Wednesday, October 30, 2024. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the presentation on the "Events & Presentations" section of the company's investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc. iRhythm is a lea
SAN FRANCISCO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended June 30, 2024. Second Quarter 2024 Financial Highlights Revenue of $148.0 million, a 19.3% increase compared to second quarter 2023Gross margin of 69.9%, a 40-basis point increase compared to second quarter 2023Unrestricted cash, cash equivalents and marketable securities of $561.5 million as of June 30, 2024Increased fiscal year 2024 guidance for revenue, gross margin, and adjusted EBITDA Recent Operational Highlights R
SAN FRANCISCO, July 18, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the second quarter 2024 after the close of trading on Thursday, August 1, 2024. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the presentation on the "Events & Presentations" section of the company's investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc. iRhythm is a leadi
SAN FRANCISCO, May 02, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended March 31, 2024. First Quarter 2024 Financial Highlights Revenue of $131.9 million, a 18.4% increase compared to first quarter 2023Gross margin of 66.3%, a 160-basis point decline compared to first quarter 2023Unrestricted cash, cash equivalents and marketable securities of $569.1 million as of March 31, 2024Increased fiscal year 2024 revenue guidance to a range of $578 million to $588 million Recent Opera
SAN FRANCISCO, April 18, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the first quarter 2024 after the close of trading on Thursday, May 2, 2024. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the presentation on the "Events & Presentations" section of the company's investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc. iRhythm is a leading
SAN FRANCISCO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months and full year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights Grew fourth quarter 2023 patient registrations in excess of 22% compared to the fourth quarter 2022Revenue of $132.5 million, a 17.7% increase compared to fourth quarter 2022Gross margin of 66.0%, a 390 basis point decrease compared to fourth quarter 2022Net loss of $38.7 million, an $18.5 million increased loss compared to fourth quarter 2022Adjuste
SAN FRANCISCO, Feb. 08, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the fourth quarter and full year 2023 after the close of trading on Thursday, February 22, 2024. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the presentation on the "Events & Presentations" section of the company's investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc. i
SAN FRANCISCO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three and nine months ended September 30, 2023. Third Quarter 2023 Financial Highlights Revenue of $124.6 million, a 20.0% increase compared to third quarter 2022Gross margin of 66.2%, a 210-basis point decline compared to third quarter 2022Cash, cash equivalents and marketable securities of $158.5 million as of September 30, 2023Increased fiscal year 2023 revenue guidance to a range of $487.5 million to $490 million Recent Operational High
SAN FRANCISCO, Oct. 19, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the third quarter 2023 after the close of trading on Thursday, November 2, 2023. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Investors interested in listening to the conference call may do so by accessing the live and archived webcast of the event available on the investors section of the Company's website at investors.irhythmtech.com. About iRhythm Techn
10-Q - iRhythm Technologies, Inc. (0001388658) (Filer)
8-K - iRhythm Technologies, Inc. (0001388658) (Filer)
8-K - iRhythm Technologies, Inc. (0001388658) (Filer)
8-K - iRhythm Technologies, Inc. (0001388658) (Filer)
10-Q - iRhythm Technologies, Inc. (0001388658) (Filer)
8-K - iRhythm Technologies, Inc. (0001388658) (Filer)
8-K - iRhythm Technologies, Inc. (0001388658) (Filer)
SD - iRhythm Technologies, Inc. (0001388658) (Filer)
10-Q - iRhythm Technologies, Inc. (0001388658) (Filer)
8-K - iRhythm Technologies, Inc. (0001388658) (Filer)
Goldman initiated coverage of iRhythm with a rating of Neutral and set a new price target of $78.00
Wolfe Research upgraded iRhythm from Peer Perform to Outperform and set a new price target of $115.00
Citigroup upgraded iRhythm from Neutral to Buy and set a new price target of $110.00
Robert W. Baird initiated coverage of iRhythm with a rating of Outperform and set a new price target of $130.00
Wells Fargo initiated coverage of iRhythm with a rating of Overweight and set a new price target of $150.00
Wolfe Research upgraded iRhythm from Underperform to Peer Perform
Citigroup downgraded iRhythm from Buy to Neutral and set a new price target of $155.00 from $180.00 previously
Wolfe Research initiated coverage of iRhythm with a rating of Underperform and set a new price target of $105.00
Morgan Stanley reiterated coverage of iRhythm Technologies with a rating of Overweight and set a new price target of $151.00 from $167.00 previously
Needham upgraded iRhythm from Hold to Buy
5 analysts have shared their evaluations of iRhythm Technologies (NASDAQ:IRTC) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 2 0 0 0 2M Ago 0 0 0 0 0 3M Ago 2 0 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $127.8, with a high estimate o
Truist Securities analyst David Rescott maintains iRhythm Technologies (NASDAQ:IRTC) with a Buy and lowers the price target from $145 to $134.
Morgan Stanley analyst Cecilia Furlong maintains iRhythm Technologies (NASDAQ:IRTC) with a Overweight and lowers the price target from $135 to $130.
These mid-cap stocks were the best performers in the last week. Are they in your portfolio? Bilibili Inc. (NASDAQ:BILI) shares rose 23.32% following last week’s release of ‘San Guo: Mou Ding Tian Xia.’ Also, JP Morgan analyst Daniel Chen upgraded Bilibili from Neutral to Overweight and announced a $21 price forecast. ImmunityBio, Inc. (NASDAQ:IBRX) shares jumped 22.36% on continued strength after the announcement of insurance coverage of ANKTIVA across multiple states with the first commercial doses administered. Sasol Ltd. (NYSE:SSL) shares escalated 20.89% after the company announced that the court ruled in favor of the company and TotalEnergies SE (NYSE:TTE) Marketing. Also, it
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Wolfe Research analyst Mike Polark upgraded the rating for iRhythm Technologies, Inc. (NASDAQ:IRTC) from Peer Perform to Outperform and announced a price target of $115. iRhythm Technologies shares gained 2.5% to close at $98.16 on Wednesday. See how other analysts view this stock. Evercore ISI Group analyst John Pancari upgraded Bread Financial Holdings, Inc. (NYSE:BFH) from Underperform to In-Line and boosted the price target from $42 to $45. Bread Finl shares gained 0.5% to close at
Wolfe Research analyst Mike Polark upgrades iRhythm Technologies (NASDAQ:IRTC) from Peer Perform to Outperform and announces $115 price target.
These mid-cap stocks were the best performers in the last week. Are they in your portfolio? Agios Pharmaceuticals Inc (NASDAQ:AGIO) shares soared 29.13% in the last week after reporting that its transfusion-dependent (TD) alpha-or beta-thalassemia study met primary endpoint. Several analysts raised their forecasts after the announcement. Verint Systems Inc. (NASDAQ:VRNT) shares are zoomed 22.40% after the company on Tuesday reported better-than-expected Q1 financial results and issued strong FY25 guidance. Novavax Inc (NASDAQ:NVAX) shares gained 21.54% in the last week after the U.S. Food and Drug Administration’s advisory committee voted to recommend updated vaccines for JN.1-line
SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)
SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)
SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)
SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)
SC 13G - iRhythm Technologies, Inc. (0001388658) (Subject)
SC 13G - iRhythm Technologies, Inc. (0001388658) (Subject)
SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)
SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)
SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)
SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)
iRhythm is the first medical device company to join the Epic community, using Aura to drive efficiencies through EHR integrationThe collaboration will expand access to Zio service across the continuum of patient care—from cardiology to primary care to emergency departments and beyond1 SAN FRANCISCO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare company focused on creating trusted solutions that detect, predict, and prevent disease, today announced it will use Epic's Aura platform to streamline access to iRhythm's Zio long-term continuous monitoring and ambulatory mobile cardiac telemetry services ("Zio services") through improved
A seasoned leader, Sung brings deep finance, capital markets, and strategy experience across the medical device industry Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, announced today that Derrick Sung has been appointed chief financial officer of the company. Sung brings over 25 years of finance, capital markets, and strategy experience across diverse roles within the medical device industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231120576987/en/Derrick Sung has been appointed chief financial officer
SAN FRANCISCO, June 06, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the appointment of Mojdeh Poul and Brian Yoor as directors to its Board effective June 1, 2023. "On behalf of the entire iRhythm team, I am thrilled to welcome Mojdeh and Brian to our Board of Directors," said Quentin Blackford, iRhythm's President and CEO. "Both bring extensive operational experience, strong financial acumen, and public company leadership across the global healthcare and medical technology sectors. We believe their proven track record of delivering
SAN FRANCISCO, July 25, 2022 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced the appointment of two seasoned executives to its leadership team. Brice Bobzien will join the company as the Chief Financial Officer on August 8, 2022, to lead all financial operations of the company as well as to advance the culture of operational excellence and prepare the company for future growth. Reyna Fernandez will join as the company's Executive Vice President, Chief Human Resources Officer on July 25, 2022, to lead the development and implementation of human resources strategies in sup
SAN FRANCISCO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) ("iRhythm"), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced the appointment of Karen Ling, an experienced HR leader, to its Board of Directors effective November 1, 2021. Ms. Ling was appointed as a Class 1 Director. The company also announced the retirement of Raymond Scott from the Board, effective November 1, 2021. Mr. Scott joined the iRhythm Board in 2013. "On behalf of the entire iRhythm team, I am pleased to welcome Karen to our Board of Directors," said Quentin Blackford, iRhythm President and CEO. "Karen is a renowned HR leader in t
SAN FRANCISCO, Dec. 14, 2020 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced that Kevin King will retire as President and CEO effective January 12, 2021. Mr. King will continue to serve on iRhythm's board of directors and as an advisor to the business. Effective the same date, Mike Coyle will join the company as President and CEO and as a member of its board of directors. Under King’s leadership, iRhythm successfully completed an IPO in 2016, achieved record financial growth and increased shareholder value significantly. During his tenure, the company’s annual revenue